NCT06195709 (ECLECTIC) is a Phase 3 clinical trial of Endocrine therapy in Breast Carcinoma, sponsored by Institut Curie.

Who is sponsoring NCT06195709?

NCT06195709 is sponsored by Institut Curie.

What drugs are being tested in NCT06195709?

Interventions in NCT06195709: Endocrine therapy, Endocrine therapy combined with the local treatment of FES-negative lesions, Chemotherapy.

What condition does NCT06195709 study?

NCT06195709 studies Breast Carcinoma.

Is NCT06195709 still recruiting?

NCT06195709 is currently recruiting now. Last updated 17 April 2026.

Last reviewed 2026-04-17 · How we verify

NCT06195709: ECLECTIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Recruiting now Phase 3 Last updated 17 April 2026

What this trial tests

Phase 3 trial testing Endocrine therapy in Breast Carcinoma in 300 participants. Currently enrolling.

Timeline

27 May 2024

Primary endpoint
27 September 2029

27 September 2030

Quick facts

Lead sponsor	Institut Curie
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	300
Start date	27 May 2024
Primary completion	27 September 2029
Estimated completion	27 September 2030
Sites	21 locations across France

Drugs / interventions tested

Endocrine therapy (endocrine-therapy) — full drug profile →
Endocrine therapy combined with the local treatment of FES-negative lesions
Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Breast Carcinoma — all drugs for Breast Carcinoma →

Sponsor

Institut Curie — full company profile →

Who can join

18 and older, any sex, with Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review.
Panda VK, Mishra B, Mahapatra S, Swain B, et al · · 2025 · cited 17× · PMID 39858015 · DOI 10.3390/cancers17020234
Circulating tumor cells in breast cancer: clinical validity and utility.
Thomas-Bonafos T, Pierga JY, Bidard FC, Cabel L, et al · · 2024 · cited 16× · PMID 39613809 · DOI 10.1038/s41523-024-00706-7

Verify or expand the search:

Other trials of Endocrine therapy

Trials testing the same drug.

NCT07005557 — Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT06369285 — A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Meta · Phase 2 · recruiting
NCT06548919 — Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer · recruiting
NCT06044623 — Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast · Phase 3 · recruiting
NCT05983107 — Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer · Phase 2 · recruiting

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

NCT07067138 — A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS- · NA · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07338721 — Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting

Other Institut Curie trials

Trials by the same sponsor.

NCT07357948 — Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy · NA · not yet recruiting
NCT07491380 — Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TD · NA · not yet recruiting
NCT07193394 — Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer · Phase 2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
NCT06659705 — Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06195709 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Curie
Last refreshed: 17 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06195709.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing